Fungizole 50mg Tablet

Dosage in Adults Infection Loading Dose Maintenance Dose Intravenous infusion Intravenous infusion Oral tablets Oral suspension Invasive Aspergillosis 6 mg/kg every 12 hours for the first 24 hours 4 mg/kg every 12 hours 200 mg every 12 hours 5 mL every 12 hours Candidemia in nonneutropenics and other deep tissue Candida infections 3–4 mg/kg every 12 hours 200 mg every 12 hours 5 mL every 12 hours Scedosporiosis and Fusariosis 4 mg/kg every 12 hours 200 mg every 12 hours 5 mL every 12 hours Esophageal Candidiasis Not Evaluated Not Evaluated 200 mg every 12 hours 5 mL every 12 hours o Adult patients weighing less than 40 kg: oral maintenance dose 100 mg or 150 mg every 12 hours o Hepatic Impairment: Use half the maintenance dose in adult patients with mild to moderate hepatic impairment (Child-Pugh Class A and B) o Renal Impairment: Avoid intravenous administration in adult patients with moderate to severe renal impairment (creatinine clearance <50 mL/min), Dosage in Pediatric Patients 2 years of age and older o For pediatric patients 2 to less than 12 years of age and 12 to 14 years of age weighing less than 50 kg see Table below.

Directions from the U.S. FDA-approved label for Voriconazole — your doctor or pharmacist may advise differently.

VFEND is contraindicated in patients with known hypersensitivity to voriconazole or its excipients. There is no information regarding cross-sensitivity between VFEND and other azole antifungal agents. Refer to the prescribing information for other azole antifungal agents., Concomittant use of VFEND with the interacting drugs described and listed below in this section are a guide and not considered a comprehensive list of all possible drugs that may be contraindicated with VFEND.

Excerpt from the U.S. FDA-approved label for Voriconazole. Talk to a pharmacist or doctor before use.

Hepatic Toxicity: Serious hepatic reactions reported. Evaluate liver function tests at start of and during VFEND therapy, Arrhythmias and QT Prolongation: Correct potassium, magnesium, and calcium prior to use; caution patients with proarrhythmic conditions, Infusion Related Reactions (including anaphylaxis): Stop the infusion, Visual Disturbances (including optic neuritis and papilledema): Monitor visual function if treatment continues beyond 28 days, Severe Cutaneous Adverse Reactions: Discontinue for exfoliative cutaneous reactions, Photosensitivity: Avoid sunlight due to risk of photosensitivity…

Warnings and precautions excerpt from the U.S. FDA-approved label for Voriconazole — not a complete list. Talk to a pharmacist or doctor before use.

The following serious adverse reactions are described elsewhere in the labeling: Hepatic Toxicity Arrhythmias and QT Prolongation Infusion Related Reactions Visual Disturbances Severe Cutaneous Adverse Reactions Photosensitivity Renal Toxicity, Adult Patients: The most common adverse reactions (incidence ≥2%) were visual disturbances, fever, nausea, rash, vomiting, chills, headache, liver function test abnormal, tachycardia,…

Excerpt from the U.S. FDA-approved label for Voriconazole — not a complete list. Talk to a pharmacist or doctor about side effects.

6 brands · 4 makers in the NepalDoc catalog — see the full Voriconazole guide →

16.2 Storage VFEND I.V. for Injection unreconstituted vials should be stored at 15°C to 30°C (59°F to 86°F). VFEND is a single dose unpreserved sterile lyophile. From a microbiological point of view, following reconstitution of the lyophile with Water for Injection, the reconstituted solution should be used immediately.

Storage information from the U.S. FDA-approved label for Voriconazole.